A possible cause of joint destruction in septic arthritis

por Krieg, Arthur M
Publicado 1999

Targeting LDL Cholesterol With LNA

por Krieg, Arthur M
Publicado 2012

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

por Aartsma-Rus, Annemieke, Krieg, Arthur M.
Publicado 2017

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity

por Chu, Rose S., Targoni, Oleg S., Krieg, Arthur M., Lehmann, Paul V., Harding, Clifford V.
Publicado 1997

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers

por Cooper, Curtis L, Ahluwalia, Navneet K, Efler, Susan M, Vollmer, Jörg, Krieg, Arthur M, Davis, Heather L
Publicado 2008

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

por Goyenvalle, Aurélie, Jimenez-Mallebrera, Cecilia, van Roon, Willeke, Sewing, Sabine, Krieg, Arthur M., Arechavala-Gomeza, Virginia, Andersson, Patrik
Publicado 2023

Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers

por Subramanian, Romesh R., Wysk, Mark A., Ogilvie, Kathleen M., Bhat, Abhijit, Kuang, Bing, Rockel, Thomas D., Weber, Markus, Uhlmann, Eugen, Krieg, Arthur M.
Publicado 2015

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

por Vollmer, Jörg, Tluk, Sibylle, Schmitz, Claudia, Hamm, Svetlana, Jurk, Marion, Forsbach, Alexandra, Akira, Shizuo, Kelly, Kindra M., Reeves, Westley H., Bauer, Stefan, Krieg, Arthur M.
Publicado 2005

Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

por Uhlik, Mark, Pointing, Daniel, Iyer, Seema, Ausec, Luka, Štajdohar, Miha, Cvitkovič, Robert, Žganec, Matjaž, Culm, Kerry, Santos, Valerie Chamberlain, Pytowski, Bronislaw, Malafa, Mokenge, Liu, Hong, Krieg, Arthur M., Lee, Jeeyun, Rosengarten, Rafael, Benjamin, Laura
Publicado 2023

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

por Ribas, Antoni, Medina, Theresa, Kirkwood, John M., Zakharia, Yousef, Gonzalez, Rene, Davar, Diwakar, Chmielowski, Bartosz, Campbell, Katie M., Bao, Riyue, Kelley, Heather, Morris, Aaron, Mauro, David, Wooldridge, James E., Luke, Jason J., Weiner, George J., Krieg, Arthur M., Milhem, Mohammed M.
Publicado 2021

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Adv...

por Negrao, Marcelo V., Papadimitrakopoulou, Vassiliki A., Price, Andrew C., Tam, Alda L., Furqan, Muhammad, Laroia, Sandeep T., Massarelli, Erminia, Pacheco, Jose, Heymach, John V., Tsao, Anne S., Walker, Gary V., Vora, Lalit, Mauro, David, Kelley, Heather, Wooldridge, James E., Krieg, Arthur M., Niu, Jiaxin
Publicado 2022